News

The companies have signed an agreement in December 2016 to jointly develop and commercialize the drug, called vadadustat. The deal called for Akebia to receive $265m in committed funds,

This designation is based on results from the ongoing, dose-ranging Phase 1-2 study that show a near cessation of spontaneous bleeding in patients with severe disease at up

The round included new strategic investments from Amgen Ventures, as well as participation from all existing investors Lux Capital, Redmile Group, dRx Capital (a Qualcomm and Novartis joint

Tagrisso 40mg and 80mg once-daily oral tablet were approved in around 45 countries, including the US, EU, Japan and China, to treat patients with EGFR T790M mutation-positive advanced

Clinical cure was the primary endpoint of the study and defined as a complete resolution of all signs and symptoms of infection. In addition, patients treated with Zavicefta

Kevzara is an investigational human monoclonal antibody directed against the IL-6 receptor. Elias Zerhouni, M.D., President, Global R&D, Sanofi said: “Rheumatoid arthritis is a painful and debilitating disease

Under the deal, Fresenius Kabi will pay $34.00 per Akorn share, in addition to assuming around $450m of debt. Akorn is engaged in the development, manufacturing and marketing

The marketing authorization of the gene therapy was approved in 2012 for the treatment of patients with familial lipoprotein lipase deficiency (LPLD). According to the Dutch gene therapy

NGM282, which is a non-tumorigenic, engineered variant of the human hormone FGF19, demonstrated a significant reduction in liver fat content and improvement of biomarkers associated with the resolution